Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stacy Danielson

Physician Assistant Rapid City, SD Physician Assistant

NPI 1114395597 CMS profile 10848420

915 Mountain View Rd, Rapid City, SD 57702

Open in the dashboard

General payments

$2,007

74 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stacy Danielson of Rapid City, SD is reported in the CMS Open Payments database as having received $2,007 across 74 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $281 13
2024 General $505 6
2023 General $170 5
2022 General $613 22
2021 General $438 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stacy Danielson
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Stacy Danielson were reported at $281. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Stacy Danielson Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $438 $132 $37–$438 $132
2022 $613 $155 $48–$522 $149
2023 $170 $167 $52–$557 $160
2024 $505 $178 $55–$600 $164
2025 $281 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alkermes, Inc. $505 16 payments
  2. Otsuka America Pharmaceutical, Inc. $228 8 payments
  3. Axsome Therapeutics, Inc. $216 2 payments
  4. E.R. Squibb & Sons, L.L.C. $143 2 payments
  5. AbbVie, Inc. $142 6 payments
  6. Janssen Pharmaceuticals, Inc $128 7 payments
  7. ITI, Inc. $105 5 payments
  8. Lundbeck LLC $99 6 payments
  9. Otsuka Pharmaceutical Development & Commercialization, Inc. $92 1 payment
  10. Neurocrine Biosciences, Inc. $64 3 payments
  11. Other $286 18 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,007 74 payments
Products named General payments · program years 2021–2025
  1. LYBALVI Cns $491 15 payments
  2. LYBALVI Cns $324 8 payments
  3. ARISTADA Cns $267 14 payments
  4. ARISTADA Cns $267 14 payments
  5. LYBALVI Cns $238 2 payments
  6. LYBALVI Cns $238 2 payments
  7. Auvelity $216 2 payments
  8. REXULTI $183 5 payments
  9. ARISTADA Cns $181 8 payments
  10. ARISTADA Cns $181 8 payments
  11. Other $1,348 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

74 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record